Silver Lake Acquires Grupo BC from L-GAM
19.10.2021 10:00:00 EEST | Business Wire | Press release
Grupo BC, the leading mortgage management, legal and digital services provider to the financial sector in Iberia and Latin America, today announced that Silver Lake, a leading global technology investment firm, together with Grupo BC’s founding shareholders and management team, will acquire 100% of the company from majority holders L-GAM in order to foster the next phase of Grupo BC’s growth and value creation.
Santiago Bellver, Chairman of Grupo BC, and Xavier Costa, CEO of Grupo BC, said: “We are grateful to L-GAM for the support and collaboration over the six years of their investment in Grupo BC, and delighted about the new partnership with Silver Lake, a leading global technology investor which has placed their trust in us and with whom we will be able to strengthen our organic growth thanks to their technological expertise and through selective acquisitions. We will shortly communicate the objectives of our strategic plan and the composition of the new Board of Directors.”
Christian Lucas, Co-Head of Silver Lake EMEA, said: “Grupo BC is an outstanding company with a unique value proposition as a scaled and tech-enabled provider of mission-critical services and software to financial institutions across Iberia and Latin America. We are impressed by the way Santiago, Xavier and the rest of the team have developed and continuously digitalized the Grupo BC platform over the years, building it into the partner of choice for clients across its ecosystem. Investing in impactful, leading and technology-enabled business models is at the core of Silver Lake’s DNA, and we feel privileged to partner with management as Grupo BC enters a new phase of organic and inorganic growth.”
Felipe Merry del Val and Tito Soso, Partners at L-GAM, added: “Our journey with Grupo BC has been a remarkable story of transformation, several fold growth and success, and importantly a hugely rewarding partnership with a world-class management team led by Chairman Santiago Bellver and CEO Xavier Costa, whom we thank for the tremendous effort and achievement. We wish Grupo BC continued success in their future exciting endeavours.”
Founded in 1974 and headquartered in Madrid, Grupo BC is the leading tech-enabled processing platform, software and services provider for mortgage management, online mortgage brokerage, legal solutions (claims processing and loan management), and digital solutions to the financial sector in Spain, Portugal, Mexico, Brazil, Colombia, Chile and Peru. Grupo BC is a market leader across its key focus areas with more than 500,000 mortgage files processed per year and 5,300 employees. For more information, please visit https://www.grupobc.com.
Silver Lake’s investment is intended to further product development in order to strengthen and expand Grupo BC’s solution range as well as to continue its track-record of pioneering digital innovation, consistent with management’s clear focus on building out Grupo BC’s software and data analytics capabilities to enhance its client-centric solutions and drive continued organic and inorganic growth.
The transaction is anticipated to close in November 2021. Further terms of the investment are not being disclosed. Socios Financieros and Canson Capital Partners served as the financial advisors to Grupo BC and its shareholders. dwf-RCD served as the legal advisor to Grupo BC and its shareholders. Paul, Weiss, Rifkind, Wharton & Garrison LLP and Uría Menéndez served as the legal advisor to Silver Lake.
About Silver Lake
Silver Lake is a global technology investment firm, with more than $88 billion in combined assets under management and committed capital and a team of professionals based in North America, Europe and Asia. Silver Lake's portfolio companies collectively generate more than $221 billion of revenue annually and employ more than 526,000 people globally. For more information about Silver Lake and its portfolio, please visit http://www.silverlake.com.
About L-GAM
L-GAM is an international investment company founded in 2013 by its professionals in partnership with the Princely House of Liechtenstein and other major European, Asian and American families. Its unique and differentiated business model is based on a long term, industrial like investment focus in partnership with highly reputed SMEs throughout Europe. For more information about L-GAM, please visit http://www.l-gam.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211019005511/en/
Contact information
Media
For Silver Lake:
Spain: Paula Bonet, paula.bonet@edelman.com, +34 629 814 440
International: Jess Gill, Edelman Smithfield, silverlakemedia@edelman.com, +44 (0)7980 684 247
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom